Spironolactone and Weight Gain in PCOS: What the Trials Measured

Does Spironolactone Cause Weight Gain in PCOS?

Four separate pieces of trial evidence have measured body weight or BMI in women with PCOS taking spironolactone, and none found a significant change in either direction. A 2026 systematic review that searched specifically for spironolactone-in-PCOS trials found five eligible open-label RCTs, and reported that spironolactone, alone or combined with metformin, showed no statistically significant difference in Ferriman-Gallwey score, total testosterone, or BMI compared with metformin monotherapy. A broader 2023 meta-analysis pooling 24 randomized trials across PCOS and idiopathic hirsutism reached the same conclusion independently, reporting that low-dose spironolactone displays no effect on FSH, LH, menstrual cyclicity, BMI, and HOMA-IR in PCOS women. Two earlier randomized trials had already shown the same pattern directly: a 2004 trial randomizing 82 adolescent and young women with PCOS (69 completed) to spironolactone 50 mg/day or metformin 1000 mg/day for six months found BMI, waist-to-hip ratio, and blood pressure did not change with either drug, and a 2013 trial randomizing 198 women with PCOS (169 completed) to metformin, low-dose spironolactone, or both combined for six months found no significant change in body weight, BMI, waist-hip ratio, or blood pressure in any of the three groups.

That is a genuinely different picture from what a search for this exact question turns up, which is individual anecdotes running in both directions with no trial data attached to either claim. The honest complication behind that gap is what the rest of this page reports: most spironolactone research was never designed to answer a weight question at all, because weight was not the outcome the trials were built to test.

Why Would a Diuretic Cause Weight Gain in the First Place?

Spironolactone is not related, mechanistically, to any pathway that causes fat gain. It works as a potassium-sparing diuretic and an antagonist at the aldosterone receptor, which means its direct physiological effect runs toward the body holding less sodium and water, not more — the opposite direction from what “weight gain” implies. In PCOS, spironolactone is prescribed off-label for its separate, unrelated action at the androgen receptor, where it blocks testosterone’s effect on hair follicles and oil glands. Neither of those two mechanisms — the diuretic effect or the androgen-blocking effect — has a known pathway to fat storage, insulin signaling, or appetite, which is exactly why the trials above measured no BMI change: there is no known mechanism for one to produce.

This runs opposite to what people expect from a drug rumored to cause weight gain. A corticosteroid or certain antipsychotics earn that reputation through a plausible pathway — appetite stimulation, hormonal fluid retention, or a direct metabolic effect. Spironolactone shares none of those pathways. If its use produces any measurable scale change in the first days of treatment, the mechanism points toward a small net fluid loss, not a gain — because that is what a diuretic does.

What Did the Trials That Measured Weight Actually Find?

That last row is the finding worth naming plainly: the largest, most recent, placebo-controlled spironolactone trial ever run — 410 women, six months, published in the BMJ in 2023 — did not report body weight as an outcome at all. Its adverse-reaction reporting flagged headache as more common on spironolactone than placebo (20% versus 12%), which shows the trial tracked side effects carefully — weight simply was not one of them. “Not measured” is a different, more honest statement than “measured and found fine,” and it is worth knowing which one is true before treating an absence of reported harm as proof of safety.

Why Do So Many People Report Gaining Weight on It, Then?

Trial averages and individual experience are not the same measurement, and the gap between them explains most of what shows up in forums and reviews. A trial reports the mean change across a group; an individual reports one data point, at one moment, often measured against a scale reading taken under different conditions — different time of day, different point in the menstrual cycle, different hydration status — than the baseline she is comparing it to. None of the trials above were designed to rule out day-to-day fluctuation in a single person; they were designed to detect a group-level average effect, and they did not find one.

Timing is the second, more concrete factor. Spironolactone for PCOS hirsutism is frequently started alongside a combined hormonal contraceptive — the pill suppresses ovarian androgen production, and reliable contraception is required while taking spironolactone anyway. The pill carries its own separate cautions: it is generally avoided with a personal history of blood clots or venous thromboembolism, with migraine with aura, with uncontrolled high blood pressure, and in smokers over 35, because of raised ischaemic stroke risk — questions for the prescriber before starting, not after.

If weight changes in the weeks after starting both drugs together, blaming spironolactone specifically — rather than the contraceptive or an unrelated change in that period of someone’s life — is a reasonable-sounding guess the trial data above does not support as the likelier explanation.

Could the Scale Move for a Reason That Has Nothing to Do With Fat?

Yes, and distinguishing fluid from fat matters because they respond to completely different things. A diuretic’s own pharmacology explains a pattern that gets misread as “the drug stopped working” or “the drug is now causing gain.” In the first days of any diuretic, sodium and water losses are at their largest; over the following one to two weeks, the body’s fluid compartments re-equilibrate around the new baseline, and further net change from the drug itself levels off. A person weighing herself daily through that transition can watch the number drop for a week and then hold roughly steady — a pattern that is easy to misread as “the initial loss reversed” when what actually happened is that the diuretic effect reached its physiological floor.

None of the four factors above are about weight. They are listed here because spironolactone’s actual, evidence-backed safety conversation is about potassium, not the scale — and a reader searching “spironolactone and weight gain” deserves to leave knowing what the drug’s real monitoring requirement is, even though it is a different question than the one she came with.

What Does the Potassium Caution Actually Feel Like?

Spironolactone’s potassium-sparing effect is the reason prescribers order follow-up bloodwork, and it deserves a plain description rather than a statistic alone. Elevated potassium (hyperkalemia) does not reliably announce itself, and when it does produce symptoms, they show up as muscle weakness, palpitations or an irregular heartbeat, and numbness or tingling — sensations easy to write off as tiredness, caffeine, or anxiety, which is exactly why they get missed. A blood test, not how you feel day to day, is the reliable way to check it, and it is a simple test your prescriber can order at a routine visit. If you notice any of those three symptoms while taking spironolactone, treat it as a same-day call to your prescriber rather than something to monitor at home first.

Why Does Reliable Contraception Matter Here Too?

Spironolactone is teratogenic — its androgen-blocking mechanism can feminize the genitals of a male fetus — which is why reliable contraception is required for anyone taking it who could become pregnant, independent of anything to do with weight. This is not a side conversation: it is the other safety condition that travels with spironolactone wherever it is prescribed, and it is worth repeating here precisely because a page about weight is not the page most people expect to find it on. Confirm your contraception is reliable before starting, and tell your prescriber immediately if you suspect pregnancy while taking it.

Who This Page Cannot Answer For

This page reports what group-level trial data shows, and group averages cannot predict any one person’s result. If your weight has genuinely changed since starting spironolactone, this data does not rule that out for you individually — it means the mechanism does not explain it, and something else is more likely to: a co-prescribed medication, a separate health change, or one of the other PCOS-driven mechanisms behind weight gain, which run through insulin, androgens, appetite hormones, and energy expenditure — pathways spironolactone does not touch. Its actual, tested purpose is hirsutism and how androgens cause it, not weight, cycles, or fertility.

None of the trials above ran longer than six months, so this page cannot tell you what happens at two or five years of use — nobody has published that data yet. For a weight-focused treatment plan rather than an androgen symptom, what actually works for PCOS weight loss covers the diet, metformin, and GLP-1 interventions trials have tested for that specific outcome. For the dosing history and full potassium data behind spironolactone itself, the dose, timeline, and potassium rule covers ground this page does not; for every other tested driver of weight change in PCOS, the full weight-loss topic index covers what does have trial data behind it.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS) after a 2026 global consensus of more than 50 organisations renamed it. The trial data and cautions above are unchanged by the rename; this article uses PCOS because that is still what most people search. The 2023 international PCOS guideline that informs care for the condition does not single out spironolactone’s weight effect either — another sign this is a narrow, specific question the largest trials simply were not built to chase.